In addition, we also explored the compatibility of a hybrid hydrazone derivative; H2 [N'-(2-chlorobenzylidene)-4-(2-(dimethylamino)ethoxy)] (26) with rMV-BNiP3 as an anti-tumor approach against breast carcinoma cells. Here, BNIP3 is linked to breast carcinoma.